RU2012136921A - Твердые формы, содержащие производные циклопропиламида - Google Patents
Твердые формы, содержащие производные циклопропиламида Download PDFInfo
- Publication number
- RU2012136921A RU2012136921A RU2012136921/04A RU2012136921A RU2012136921A RU 2012136921 A RU2012136921 A RU 2012136921A RU 2012136921/04 A RU2012136921/04 A RU 2012136921/04A RU 2012136921 A RU2012136921 A RU 2012136921A RU 2012136921 A RU2012136921 A RU 2012136921A
- Authority
- RU
- Russia
- Prior art keywords
- solid form
- form according
- schizophrenia
- xrpd
- essentially
- Prior art date
Links
- 239000007787 solid Substances 0.000 title claims abstract 34
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical class NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 title 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract 12
- 230000005855 radiation Effects 0.000 claims abstract 8
- 238000001757 thermogravimetry curve Methods 0.000 claims abstract 5
- 238000002411 thermogravimetry Methods 0.000 claims abstract 4
- 150000001875 compounds Chemical class 0.000 claims abstract 2
- 238000000113 differential scanning calorimetry Methods 0.000 claims abstract 2
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims abstract 2
- 201000000980 schizophrenia Diseases 0.000 claims 10
- 230000001149 cognitive effect Effects 0.000 claims 6
- 230000007812 deficiency Effects 0.000 claims 6
- 208000024827 Alzheimer disease Diseases 0.000 claims 5
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 5
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 5
- 208000008589 Obesity Diseases 0.000 claims 5
- 208000002193 Pain Diseases 0.000 claims 5
- 206010041349 Somnolence Diseases 0.000 claims 5
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 5
- 201000003631 narcolepsy Diseases 0.000 claims 5
- 235000020824 obesity Nutrition 0.000 claims 5
- 208000028698 Cognitive impairment Diseases 0.000 claims 4
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 2
- 230000004580 weight loss Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30558110P | 2010-02-18 | 2010-02-18 | |
| US61/305,581 | 2010-02-18 | ||
| PCT/SE2011/050170 WO2011102793A1 (en) | 2010-02-18 | 2011-02-17 | Solid forms comprising a cyclopropyl amide derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012136921A true RU2012136921A (ru) | 2014-03-27 |
Family
ID=44370079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012136921/04A RU2012136921A (ru) | 2010-02-18 | 2011-02-17 | Твердые формы, содержащие производные циклопропиламида |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20110201622A1 (https=) |
| EP (1) | EP2536701A4 (https=) |
| JP (1) | JP5746718B2 (https=) |
| KR (1) | KR20130034009A (https=) |
| CN (1) | CN103140481A (https=) |
| AR (1) | AR080203A1 (https=) |
| AU (1) | AU2011218490B9 (https=) |
| BR (1) | BR112012020780A2 (https=) |
| CA (1) | CA2789884A1 (https=) |
| CL (1) | CL2012002285A1 (https=) |
| IL (1) | IL221430A0 (https=) |
| MX (1) | MX2012009537A (https=) |
| NZ (1) | NZ602108A (https=) |
| RU (1) | RU2012136921A (https=) |
| SG (1) | SG183231A1 (https=) |
| TW (1) | TW201136898A (https=) |
| WO (1) | WO2011102793A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2195293T3 (da) | 2007-08-22 | 2014-02-03 | Astrazeneca Ab | Cyclopropylamidderivater |
| TW201039825A (en) * | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
| BR112012020629A2 (pt) | 2010-02-18 | 2018-06-19 | Astrazeneca Ab | forma cristalina, e, método para a terapia de um distúrbio |
| CN109438423A (zh) * | 2018-09-12 | 2019-03-08 | 通化师范学院 | 一种肺癌靶向化合物azd-3759的合成工艺的新方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL297170A (https=) * | 1963-04-04 | 1900-01-01 | ||
| US3449427A (en) * | 1965-06-03 | 1969-06-10 | Smithkline Corp | Aminocyclopropane derivatives of 5h-dibenzo(a,d)cycloheptenes |
| US3697506A (en) * | 1970-08-07 | 1972-10-10 | Pfizer | Crystalline alkali metal salts of {60 -carboxybenzylpenicillin and process therefor |
| US3686335A (en) * | 1970-12-21 | 1972-08-22 | Smith Kline French Lab | 5-vinyl-5h-di benzo(a,d)cycloheptenes |
| US4432987A (en) * | 1982-04-23 | 1984-02-21 | Pfizer Inc. | Crystalline benzenesulfonate salts of sultamicillin |
| US4547505A (en) * | 1983-03-25 | 1985-10-15 | Degussa Aktiengesellschaft | N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production |
| DE69013131T2 (de) * | 1989-12-29 | 1995-05-24 | Banyu Pharma Co Ltd | 2-(2-Cyclopropylpyrrolidin-4-ylthio)carbapenemderivate. |
| DE4131139A1 (de) * | 1991-09-19 | 1993-03-25 | Bayer Ag | Verfahren zur herstellung von 1-fluor-cyclopropan-1-carbonsaeure |
| KR100296810B1 (ko) * | 1993-03-12 | 2001-10-24 | 로렌스 티. 마이젠헬더 | 결정성세프티오퍼유리산 |
| EP1090919A4 (en) * | 1998-06-26 | 2002-05-22 | Chugai Pharmaceutical Co Ltd | FINE POWDER OF L-ALPHA-AMINOADIPIC ACID DERIVATIVES, SOLID PREPARATIONS FOR ORAL USE AND A METHOD FOR TREATING Loose POWDER |
| US6284761B1 (en) * | 1999-01-08 | 2001-09-04 | Neurogen Corporation | 1-phenyl-4-(1-[2-aryl]cyclopropyl)methylpiperazines: dopamine receptor ligands |
| EP1248869A2 (en) * | 2000-01-07 | 2002-10-16 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
| US6521619B2 (en) * | 2000-06-29 | 2003-02-18 | Icos Corporation | Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents |
| PL364625A1 (en) * | 2001-02-23 | 2004-12-13 | Merck & Co, Inc. | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists |
| WO2003026572A2 (en) * | 2001-09-26 | 2003-04-03 | Merck & Co., Inc. | Crystalline forms of ertapenem sodium |
| US6861432B2 (en) * | 2001-11-23 | 2005-03-01 | Schering Aktiengesellschaft | Piperazine derivatives that destabilize androgen receptors |
| JP2005526800A (ja) * | 2002-03-22 | 2005-09-08 | エルジー・ライフ・サイエンシーズ・リミテッド | （２Ｓ）−Ｎ−５−［アミノ（イミノ）メチル］−２−チエニルメチル−１−（２Ｒ）−２−［（カルボキシルメチル）アミノ］−３，３−ジフェニルプロパノイル−２−ピロリジンカルボキサミド・ｎＨ２Ｏの新しい結晶形 |
| US20040077618A1 (en) * | 2002-10-22 | 2004-04-22 | Bennani Youssef L. | Cycloalkylamides and their therapeutic applications |
| US20040209858A1 (en) * | 2002-10-22 | 2004-10-21 | Bennani Youssef L. | Cycloalkylamides and their therapeutic applications |
| CA2523431A1 (en) * | 2003-04-23 | 2004-11-25 | Glaxo Group Limited | Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases |
| TWI339206B (en) * | 2003-09-04 | 2011-03-21 | Vertex Pharma | Compositions useful as inhibitors of protein kinases |
| SI1948607T1 (sl) * | 2005-09-16 | 2010-07-30 | Janssen Pharmaceutica Nv | Ciklopropil amini kot modulatorji histaminskega H3 receptorja |
| RU2008132966A (ru) * | 2006-01-13 | 2010-02-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Производные циклогексилпиперазинилметанона и их применение в качестве модуляторов гистамин н3 рецептора |
| BRPI0712823A2 (pt) * | 2006-06-23 | 2012-07-24 | Abbott Lab | derivados de ciclopropil amina como moduladores de receptor de histamina h3 |
| US9108948B2 (en) * | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
| TW200828371A (en) * | 2006-09-21 | 2008-07-01 | Matsushita Electric Industrial Co Ltd | Chip-type filter |
| DK2195293T3 (da) * | 2007-08-22 | 2014-02-03 | Astrazeneca Ab | Cyclopropylamidderivater |
| ES2460897T3 (es) * | 2007-10-04 | 2014-05-14 | F. Hoffmann-La Roche Ag | Derivados de ciclopropil aril amida y usos de los mismos |
| TW200934772A (en) * | 2008-01-15 | 2009-08-16 | Lilly Co Eli | Crystalline(R)-2-(4-cyclopropanesulphonyl-phenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide |
| TW201039825A (en) * | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
| BR112012020629A2 (pt) * | 2010-02-18 | 2018-06-19 | Astrazeneca Ab | forma cristalina, e, método para a terapia de um distúrbio |
-
2011
- 2011-02-17 US US13/029,351 patent/US20110201622A1/en not_active Abandoned
- 2011-02-17 NZ NZ602108A patent/NZ602108A/en not_active IP Right Cessation
- 2011-02-17 MX MX2012009537A patent/MX2012009537A/es not_active Application Discontinuation
- 2011-02-17 JP JP2012553848A patent/JP5746718B2/ja not_active Expired - Fee Related
- 2011-02-17 KR KR1020127024173A patent/KR20130034009A/ko not_active Withdrawn
- 2011-02-17 BR BR112012020780A patent/BR112012020780A2/pt not_active IP Right Cessation
- 2011-02-17 CA CA2789884A patent/CA2789884A1/en not_active Abandoned
- 2011-02-17 TW TW100105298A patent/TW201136898A/zh unknown
- 2011-02-17 AR ARP110100484A patent/AR080203A1/es unknown
- 2011-02-17 RU RU2012136921/04A patent/RU2012136921A/ru not_active Application Discontinuation
- 2011-02-17 AU AU2011218490A patent/AU2011218490B9/en not_active Ceased
- 2011-02-17 WO PCT/SE2011/050170 patent/WO2011102793A1/en not_active Ceased
- 2011-02-17 SG SG2012058848A patent/SG183231A1/en unknown
- 2011-02-17 CN CN201180019676XA patent/CN103140481A/zh active Pending
- 2011-02-17 EP EP20110744973 patent/EP2536701A4/en not_active Withdrawn
-
2012
- 2012-08-13 IL IL221430A patent/IL221430A0/en unknown
- 2012-08-17 CL CL2012002285A patent/CL2012002285A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012020780A2 (pt) | 2016-05-03 |
| MX2012009537A (es) | 2012-08-31 |
| NZ602108A (en) | 2014-09-26 |
| AU2011218490A1 (en) | 2012-10-04 |
| CN103140481A (zh) | 2013-06-05 |
| AU2011218490B2 (en) | 2014-11-13 |
| AU2011218490B9 (en) | 2014-12-18 |
| SG183231A1 (en) | 2012-09-27 |
| IL221430A0 (en) | 2012-10-31 |
| CA2789884A1 (en) | 2011-08-25 |
| JP2013520412A (ja) | 2013-06-06 |
| EP2536701A4 (en) | 2014-05-07 |
| JP5746718B2 (ja) | 2015-07-08 |
| TW201136898A (en) | 2011-11-01 |
| WO2011102793A1 (en) | 2011-08-25 |
| AR080203A1 (es) | 2012-03-21 |
| KR20130034009A (ko) | 2013-04-04 |
| EP2536701A1 (en) | 2012-12-26 |
| US20110201622A1 (en) | 2011-08-18 |
| CL2012002285A1 (es) | 2013-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021530565A5 (https=) | ||
| RU2012136148A (ru) | Новая кристаллическая форма производного циклопропилбензамида | |
| RU2014151565A (ru) | Способ получения n-[5-(3,5-дифторбензил)-1н-индазол-3-ил]-4-(4-метилпиперазин-1-ил)-2-(тетрагидропиран-4-иламино)бензамида | |
| RU2599785C3 (ru) | Кристаллические формы 5-хлор-n2-(2-изопропокси-5-метил-4-пиперидин-4-ил-фенил)-n4-[2-(пропан-2-сульфонил)-фенил]-пиримидин-2,4-диамина | |
| RU2014145544A (ru) | Солевая форма ингибитора гистон-метилтрансферазы ezh2 человека | |
| RU2019100065A (ru) | Кристаллы анилинпиримидинового соединения, действующего в качестве ингибитора EGFR | |
| CN110573500A (zh) | N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用 | |
| FI2744810T4 (fi) | Tenofoviirialafenamidihemifumaraatti | |
| JP2015522589A5 (https=) | ||
| RU2017117413A (ru) | Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона | |
| JP2015512942A5 (https=) | ||
| JP2010500293A5 (https=) | ||
| JP2011527333A5 (https=) | ||
| JP2010501519A5 (https=) | ||
| JP2015522037A5 (https=) | ||
| RU2012136921A (ru) | Твердые формы, содержащие производные циклопропиламида | |
| RU2019105794A (ru) | Кристаллогидрат соединения (2s, 3r) -изопропил 2 - (((2- (1,5-диметил-6-оксо-1,6-дигидропиридин-3-ил) -1 - ((тетрагидро-2h-пиран) -4-ил) метил) -1h-бензо [d] имидазол-5-ил) метил) амино) -3-гидроксибутаноат эдисилат | |
| RU2018103172A (ru) | Кристаллическая фумаратная соль (s)-[3,4-дифтор-2-(2-фтор-4-йодфениламино)фенил][3-гидрокси-3-(пиперидин-2-ил)азетидин-1-ил]метанона | |
| RU2014104993A (ru) | Кристаллическая форма натриевой соли 4-трет-бутил-n-{4-хлор-2-(1-окси-пиридин-4-карбонил)-фенил}-бензолсульфонамид | |
| MX2014010910A (es) | Sales novedosas de trimebutina basadas en sulfonato. | |
| RU2013103754A (ru) | Новые кристаллические формы n-[-2[[(2,3,-дифторфенил)метил]тио]-6-{[(1r, 2s)-2,3-дигидрокси-1-метилпропил]окси}-4-пиримидинил]-1-азатидин-сульфонамида | |
| JP2016510767A5 (https=) | ||
| RU2015114085A (ru) | Кристаллические формы производных дигидропиримидина | |
| JP2013520412A5 (https=) | ||
| JP2018140987A5 (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160210 |